A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients... April 7, 2025 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 We want every scientist to thrive in cancer research July 28, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan January 16, 2025 Load more HOT NEWS “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... Genetic Signature May Help Tailor Treatment for Meningioma EMA Recommends Granting a Marketing Authorisation for Degarelix Accord Cannabis, cannabinoids and cancer – the evidence so far
